EVG.L Share Price (EVG)

Theracryf PLC, formerly Evgen Pharma plc, is a clinical-stage drug development company.

The Company is focused on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases.

Its core technology is Sulforadex, which is a method for synthesizing and stabilizing the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.

Its asset, SFX-01, is a composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive metastatic breast cancer. SFX-01 exploits sulforaphane's activity in three separate biochemical pathways, such as inhibition of STAT3 and SHP2, of importance in controlling cancers metastases, and up-regulation of Nrf2, a pathway of significance in several different diseases.

Its pipeline includes breast cancer, glioblastoma, hematological malignancies, and analogues. It also has a licensing in neurodevelopmental disorders and schizophrenia.

MSM money

Well that transfer went smoothly, ...... not.

Bojo2020

Good to see you posting here :-)

All the best to you , and patience IS the Key here as usual ..

Looks like Vulpes were holding shares in Chronus as a private company which have now translated to an Evgen holding. There may or may not have been some additional buying.

Give us an update on the dispute notice issued to Stalicla.